Why the study?
Does sevoflurane preconditioning improve myocardial recovery and reduce infarct size via ROS-induced AMPK activation in isolated rat hearts subjected to ischemia and reperfusion?
Does sevoflurane preconditioning improve myocardial recovery and reduce infarct size via ROS-induced AMPK activation in isolated rat hearts subjected to ischemia and reperfusion?
Sevoflurane-induced cardioprotection against ischemia-reperfusion injury is mediated by reactive oxygen species-dependent activation of AMPK.
Answers are grounded in this paper and cite their sources.
ROS-dependent AMPK activation mediates sevoflurane cardioprotection in rat hearts; hypothesis-generating for clinical translation.
BACKGROUND: 5'AMP-activated protein kinase (AMPK), a well-known regulator of cellular energy status, is also implicated in ischemic preconditioning leading to cardioprotection. We hypothesized that AMPK is involved in anesthetic-induced cardioprotection and that this activation is mediated by reactive oxygen species (ROS). METHODS AND RESULTS: Isolated Langendorff-perfused rat hearts were subjected to 35 minutes of global ischemia (I) followed by 120 minutes of reperfusion (I/R). Hearts were assigned to a control group (Con) or a sevoflurane (Sevo) group receiving 3 times 5-minute episodes of sevoflurane (2.5vol%) before I/R. Phosphorylation of both AMPK and endothelial nitric oxide synthase (eNOS) were determined by Western blot analysis. Cardioprotection was assessed after I/R from recovery of left ventricular pressure and from infarct size (triphenyltetrazolium chloride staining). In the control group, ischemia resulted in a 2-fold increase in phosphorylation levels of AMPK (Con 0.13+/-0.01 versus Con-I 0.28+/-0.05, P<0.05), which was sustained after 120 minutes of reperfusion (Con-I/R 0.26+/-0.02, P<0.05). Sevoflurane preconditioning had no affect on AMPK phosphorylation before ischemia (Sevo 0.12+/-0.03, P>0.05), but almost doubled the increase in AMPK phosphorylation relative to control after ischemia (Sevo-I 0.48+/-0.09, P<0.05), an effect that was sustained after reperfusion (Sevo-I/R 0.49+/-0.12, P<0.05). The AMPK-inhibitor compound C (10 micromol/L) reduced the sevoflurane-mediated increase in phosphorylation of AMPK and its target eNOS and abolished cardioprotection. The ROS-scavenger n-(2-mercaptopropionyl)-glycine (1 mmol/L) blunted the sevoflurane-mediated increase in AMPK and eNOS phosphorylation and prevented cardioprotection. CONCLUSIONS: Sevoflurane-induced AMPK activation protects the heart against ischemia and reperfusion injury and relies on upstream production of ROS.
No takes yet. Share an insight, caveat, or question.
Lamberts et al. (2009) studied Ischemia and reperfusion injury (n=116). Sevoflurane preconditioning vs. Control (no preconditioning) was evaluated on AMPK phosphorylation after ischemia (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: